LCN2 and ganglioneuroma: Median NGAL in glomerular disease patients at baseline was about 6-fold higher than healthy subjects (NGAL1 GN: 26.1 (2.3–213.0) versus healthy, 4.4 (3.1–10.6), n = 10, p < 0.001), and about 12-fold lower than AKI controls (NGAL1 GN: 26.1 (2.3–213.0) versus AKI, 302.6 (85.9–4808), n = 19, p < 0.001).